

Hamilton Regional Laboratory Medicine Program - HRLMP (effective at Hamilton Health Sciences, St. Joseph's Hospital and Associated Health Care Facilities)			
Initial Issue Date: Revision Date:	Administration Guidelines	Section: Sub-Section:	Laboratory Medicine Transfusion Medicine
Title: SYNAGIS (Recombinant)		Document Number:	
Approved By: <i>Director, Laboratory Medicine Chair, Regional Transfusion Medicine Committee Head, Transfusion Medicine, HRLMP Manager, Transfusion Medicine, HRLMP Technical Specialist, Transfusion Medicine, HRLMP Chief of Nursing Practice, Hamilton Health Sciences Chief of Nursing Practice, St. Joseph's Healthcare</i>		Page 1 of 3	

Purpose: To establish the Indications and Administration of RSV Immune Globulin Intramuscular

Scope: Applies to all patient care areas across HHS and St. Joseph's Healthcare

Definitions: SYNAGIS is a humanized monoclonal antibody produced by recombinant DNA technology. Synagis exhibits neutralizing and inhibitory activity against Respiratory Syncytial Virus (RSV).

Other Names: RSV Immune Globulin Intramuscular; Palivizumab	Date Approved:	Pages: 1 of 3
---	-----------------------	----------------------

<p>INDICATIONS:</p> <ul style="list-style-type: none"> - Prevention of serious lower respiratory tract disease caused by Respiratory Syncytial Virus (RSV) in pediatric patients at high risk of RSV disease - Safety and efficacy were established in infants (less than 24 months) with bronchopulmonary dysplasia (BPD) and infants with history of prematurity (\leq32 weeks gestational age)
<p>DOSAGE:</p> <ul style="list-style-type: none"> - Recommended dose is 15 mg/Kg of body weight administered as an intramuscular, monthly shot throughout RSV season - RSV season in the Northern Hemisphere typically commences in November and lasts through April
<p>SUPPLIED:</p> <ul style="list-style-type: none"> - Special Access Product - must obtain Emergency Drug Release - contact Transfusion Medicine - Synagis is supplied in single use vials containing 100 mg lyophilized product - Stored between 2°C and 8°C - Do not freeze - Do not use after expiration date

RECONSTITUTION AND STABILITY:

- Available from Pharmacy
- See Manufacturer's information (package insert) for further information
- Reconstituted product should be used immediately

ADMINISTRATION:

METHOD	WHO/WHERE	DILUTION	HOW TO ADMINISTER	INFUSION PUMP	PRECAUTIONS AND MONITORING
IV PUSH	N/A	N/A	N/A	N/A	N/A
MINIBAG/ BURETROL	N/A	N/A	N/A	N/A	N/A
PRIMARY IV BAG	N/A	N/A	N/A	N/A	N/A
IM or SC	RN	No	- Administer intramuscularly - No more than 1 mL may be injected into a single site	No	- Observe and monitor for adverse reactions

COMPATIBILITIES/INCOMPATIBILITIES:

- Synagis should not be used in pediatric patients with history of a severe prior reaction to Synagis or other components of this product.
- Synagis should be given with caution to patients with severe thrombocytopenia or any coagulation disorder.
- Synagis not indicated for adult usage.
- Not known whether Synagis can cause fetal harm when administered to a pregnant woman.

ADVERSE EFFECTS:

- Study comparing patients receiving Synagis and those receiving placebo, adverse reactions were documented in both groups; these reactions were upper respiratory infection, rhinitis, rash, pain, fever, hernia, SGOT increase and pharyngitis
- Vomiting and diarrhea very rarely

MANAGEMENT OF ADVERSE EFFECTS:

- Notify Physician
- Notify Transfusion Medicine
- Epinephrine should be available for anaphylaxis or severe allergic adverse reactions

NOTES:

- Manufactured by MedImmune Inc. Gaithersburg, MD
- Co-marketed by: Ross Products Division Abbott Laboratories
- Distributed by Canadian Blood Services

Documentation:

Issue transfuse sheets or requisitions must be included in patient's chart
Written consent for transfusion is required prior to administration of initial dose

References:

Package Insert- Synagis (Palivizumab) for intramuscular injection, Med Immune, Inc., June 19, 1998

Developed By In Consultation With:

Transfusion Medicine Operations Group
Pediatric Clinical Nurse Educators
Pediatric Clinic

REVIEW DATES:

REVISION DATES: